

**Remarks**

***Rejection under 35 U.S.C. §112, second paragraph***

***Rejections under 35 U.S.C. §101***

In paragraphs 3 and 4, the Office rejects claims 15-24 as indefinite under 35 U.S.C. 112, second paragraph, for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention. In paragraph 5, the Office rejects claims 15-24 under 35 U.S.C. §101 for the recitation of a use.

To overcome these rejections, Applicants have amended the claims to conform them with U.S. claim format.

***Rejections under 35 U.S.C. §102***

In paragraphs 6 and 7, the Office rejects claim 26 under 35 U.S.C. §102(b) as anticipated by U.S. Patent No. 5,773,644 to Chen et al.

In particular, the Office alleges that Example F in column 32 of Chen et al. anticipates the compound of claim 26 when  $m=0$ ,  $Ar=phenyl$ ,  $X^1=NH_2$ .

Applicants have canceled claim 26, and formulated new compound claim 43 to exclude the compound disclosed in Example F, column 32 of Chen et al.

In paragraphs 6 and 7, the Office rejects claim 26 under 35 U.S.C. §102(b) as anticipated by U.S. Patent No. 6,022,969 to Rice et al.


In particular, the Office alleges that the 4-guanidinobenzylamine bis-trifluoroacetate disclosed in lines 8-10 of column 20 of Rice anticipates the compound of claim 26 when  $m=0$  and  $X^1=NH_2$ .

Applicants have canceled claim 26, and formulated new compound claim 43 to exclude 4-guanidinobenzylamine bis-trifluoroacetate salts when  $Ar=phenyl$ ,  $X^1=NH_2$  and  $m=0$ . Applicants respectfully submit that what Rice et al. describe in column 20 as "trifluoroacetates" are salts of 4-guanidinobenzylamine.

Applicants have also formulated the new compound claim 43 to exclude 4-guanidino-N-tert-butoxycarbonylbenzylamine hydrochloride, which is an intermediate of the synthesis of the above discussed 4-guanidinobenzylamine bis-trifluoroacetate, when  $Ar=phenyl$ ,  $X^1=NR^3R^4$  with  $R^4=H$  and  $R^3=-COOR^7$  with  $R^7=tertbutyl$  and  $m=0$ .

Applicants respectfully submit that these limitations should overcome the rejection over Rice et al.

In the event that this paper is not accompanied by the full fee required for its consideration, the Commissioner is authorized to charge any insufficient or missing fees to RFEM's deposit account No. 02-2135. The Commissioner is also authorized to deposit any overpayment to the same account. A duplicate copy for the financial branch is enclosed.

| RESPECTFULLY SUBMITTED, |   |               |              |
|-------------------------|---|---------------|--------------|
| NAME AND<br>REG. NUMBER | Joyce von Natzmer, Reg. No. 48,120  |               |              |
| SIGNATURE               |  | DATE          | 06/25/03     |
| Address                 | Rothwell, Figg, Ernst & Manbeck<br>1425 K Street, N.W., Suite 800                 |               |              |
| City                    | Washington  | State         | D.C.         |
| Country                 | U.S.A.  | Teleph<br>one | 202-783-6040 |